Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya — IGLOO  

Multiple Sclerosis-Relapsing-Remitting Clinical Trial

Official title: An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 2 Years

Status Completed

Clinical Trial Summary

This study will determine whether in RRMS patients receiving Gilenya there is a link between disease progression and biologic markers.

Clinical Trial Description

The biologic basis that determines disease progression in multiple sclerosis (MS) patients remains to be defined. We propose that a long term study of patients where inflammatory activity of the disease is expected to be controlled on treatment, will identify patients into cohorts of those whose disease is deemed to be stable with those patients whose disease has been deemed to progress. Once the two groups have been identified, it will then be possible to assess whether there are differences in biologic markers between the two groups. These markers would then have the potential to be used to monitor disease progression or be predictors for patient response to drug treatment. ;

Related Conditions & MeSH terms

• Disease Progression
• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Multiple Sclerosis-Relapsing-Remitting
• Sclerosis

• NCT number: NCT02137707
• Study type: Observational
• Source: McGill University
• Status: Completed
• Start date: November 2012
• Completion date: October 30, 2018